The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...

Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate ... Neurocrine Biosciences, Biohaven Pharma, GSK, Roche/Genentech, Takeda, Sanofi, and AbbVie.

After hours: February 19 at 5:10:43 PM EST ...

The other, Pfizer’s tafamidis, surpassed $5 billion in sales in 2024, reflecting a market some analysts expect to eventually be worth $15 billion to $20 billion annually. BridgeBio has contended its ...

After hours: 7:59:30 p.m. EST ...